靶向FIGNL1-FIRRM-MACIR复合体的抑制剂在制备肿瘤药物中的应用及其组合物
By targeting the FIGNL1-FIRRM-MACIR complex, the problem of platinum-based drug resistance in tumors such as ovarian cancer has been solved. MACIR promotes the dissociation of RAD51 filaments, thereby enhancing the efficacy of chemotherapy.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- NAT HEALTH COMMISSION INST OF SCI & TECH
- Filing Date
- 2026-04-09
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies have difficulty effectively targeting the FIGNL1-FIRRM-MACIR complex, leading to drug resistance issues in platinum-based drugs in tumors such as ovarian cancer, thus affecting the efficacy of chemotherapy.
Develop inhibitors targeting the FIGNL1-FIRRM-MACIR complex, knock down MACIR with small molecule compounds or siRNA to enhance the sensitivity of ovarian cancer cells to platinum-based drugs, and utilize MACIR as a bridge-like adaptor subunit of FIGNL1-FIRRM unfolding enzyme to promote the dissociation of RAD51 filament structure and DNA damage repair.
It significantly enhanced the cytotoxicity of ovarian cancer cells to platinum-based drugs, improved the sensitivity and efficacy of chemotherapy, and solved the problem of platinum resistance.
Smart Images
Figure CN122005808B_ABST